ACLARIS THERAPEUTICS INC's ticker is ACRS and the CUSIP is 00461U105. A total of 113 filers reported holding ACLARIS THERAPEUTICS INC in Q1 2017. The put-call ratio across all filers is - and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $35,188,000 | +2.5% | 1,954,904 | 0.0% | 48.80% | +34.1% |
| Q2 2021 | $34,328,000 | -30.3% | 1,954,904 | 0.0% | 36.39% | -15.9% |
| Q1 2021 | $49,264,000 | +369.9% | 1,954,904 | +20.7% | 43.26% | +255.0% |
| Q4 2020 | $10,483,000 | +495.6% | 1,620,244 | +136.6% | 12.18% | +830.2% |
| Q3 2020 | $1,760,000 | -10.3% | 684,912 | +157.8% | 1.31% | +103.1% |
| Q4 2018 | $1,963,000 | -56.7% | 265,694 | -14.9% | 0.64% | -35.6% |
| Q3 2018 | $4,536,000 | -27.3% | 312,368 | 0.0% | 1.00% | -25.5% |
| Q2 2018 | $6,238,000 | +14.0% | 312,368 | 0.0% | 1.34% | +12.6% |
| Q1 2018 | $5,473,000 | +4.2% | 312,368 | +46.7% | 1.19% | -19.1% |
| Q4 2017 | $5,251,000 | -22.6% | 212,950 | -19.0% | 1.47% | -21.1% |
| Q3 2017 | $6,787,000 | +62.6% | 262,950 | +87.8% | 1.87% | +16.7% |
| Q1 2017 | $4,175,000 | -1.3% | 140,000 | -10.1% | 1.60% | -12.8% |
| Q4 2016 | $4,228,000 | – | 155,767 | – | 1.84% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management III, LLC | 1,954,904 | $49,264,000 | 43.26% |
| COMMODORE CAPITAL LP | 1,028,084 | $25,908,000 | 10.32% |
| Foresite Capital Management IV, LLC | 3,399,034 | $85,656,000 | 10.26% |
| VR Adviser, LLC | 3,720,582 | $93,759,000 | 10.17% |
| Parkman Healthcare Partners LLC | 1,709,136 | $43,070,000 | 10.00% |
| Foresite Capital Management V, LLC | 1,258,243 | $31,708,000 | 9.32% |
| Stenahm Asset Managment Ltd | 283,500 | $7,144,000 | 5.04% |
| Samsara BioCapital, LLC | 1,022,612 | $25,770,000 | 4.75% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 336,737 | $8,486,000 | 4.63% |
| Ghost Tree Capital, LLC | 600,000 | $15,120,000 | 3.55% |